Tecentriq (Atezolizumab) Receives Supplemental FDA Approval for Efficacy

On May 6, 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab). This approval specifically pertains to the drug's efficacy, indicating an expansion of its approved uses based on new clinical data.

What this means

The supplemental FDA approval for Tecentriq (atezolizumab) for efficacy on May 6, 2019, signifies that the drug has demonstrated effectiveness for an additional indication or patient population. While the specific details of this expanded use are not provided in the source data, this type of approval typically allows clinicians to prescribe Tecentriq for a broader range of conditions or in new patient groups where its efficacy has been scientifically established and reviewed by the FDA. This expands the therapeutic options available to patients who may benefit from atezolizumab treatment.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 761034 S-13, concerning Tecentriq (atezolizumab), was documented on May 6, 2019, on the accessdata.fda.gov website.